Trial · NCT03589326
Participant flow22
How many started, completed or left each group, period by period.
1 to 20 of 22
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| IP (Cycles 1-3) (Cycle Length=28 Days) | STARTED | Cohort A: Ponatinib 30 mg | 164 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | STARTED | Cohort B: Imatinib 600 mg | 81 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | Efficacy Evaluable Population | Cohort A: Ponatinib 30 mg | 154 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | Efficacy Evaluable Population | Cohort B: Imatinib 600 mg | 78 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | Safety Population | Cohort A: Ponatinib 30 mg | 163 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | Safety Population | Cohort B: Imatinib 600 mg | 81 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | COMPLETED | Cohort A: Ponatinib 30 mg | 0 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | COMPLETED | Cohort B: Imatinib 600 mg | 0 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | NOT COMPLETED | Cohort A: Ponatinib 30 mg | 164 | |
| IP (Cycles 1-3) (Cycle Length=28 Days) | NOT COMPLETED | Cohort B: Imatinib 600 mg | 81 | |
| CP (Cycles 4-9) (Cycle Length=28 Days) | STARTED | Cohort A: Ponatinib 30 mg | 0 | |
| CP (Cycles 4-9) (Cycle Length=28 Days) | STARTED | Cohort B: Imatinib 600 mg | 0 | |
| CP (Cycles 4-9) (Cycle Length=28 Days) | COMPLETED | Cohort A: Ponatinib 30 mg | 0 | |
| CP (Cycles 4-9) (Cycle Length=28 Days) | COMPLETED | Cohort B: Imatinib 600 mg | 0 | |
| CP (Cycles 4-9) (Cycle Length=28 Days) | NOT COMPLETED | Cohort A: Ponatinib 30 mg | 0 | |
| CP (Cycles 4-9) (Cycle Length=28 Days) | NOT COMPLETED | Cohort B: Imatinib 600 mg | 0 | |
| MP (Cycles 10-20) (Cycle Length=28 Days) | STARTED | Cohort A: Ponatinib 30 mg | 0 | |
| MP (Cycles 10-20) (Cycle Length=28 Days) | STARTED | Cohort B: Imatinib 600 mg | 0 | |
| MP (Cycles 10-20) (Cycle Length=28 Days) | COMPLETED | Cohort A: Ponatinib 30 mg | 0 | |
| MP (Cycles 10-20) (Cycle Length=28 Days) | COMPLETED | Cohort B: Imatinib 600 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03589326/flow